Armistice Capital, LLC and Steven Boyd filed Amendment No. 3 to a beneficial ownership statement with the SEC on November 16, 2026, disclosing a combined position of 5,724,000 shares of Verastem, Inc. common stock as of September 30, 2026.
Key Highlights
- Reporting persons: Armistice Capital, LLC (Delaware-organized investment adviser) and Steven Boyd, its managing member, filed jointly as Amendment No. 3.
- Shares reported: 5,724,000 shares of Verastem, Inc. common stock, $0.0001 par value per share (CUSIP 92337C203).
- Percent of class: The 5,724,000 shares represent 0.94% of the outstanding class, according to the filing.
- Voting and dispositive power: Both reporting persons report 0 sole voting power and 0 sole dispositive power; all 5,724,000 shares are held with shared voting and shared dispositive power.
- Triggering event date: The filing identifies September 30, 2026 as the date of the event requiring this statement.
- Actual holder: The filing states that the shares are directly held by Armistice Capital Master Fund Ltd., over which Armistice Capital exercises voting and investment power pursuant to an Investment Management Agreement.
Armistice Capital's Disclosed Position in Verastem as of September 30, 2026
According to the filing, Armistice Capital, LLC serves as the investment manager of Armistice Capital Master Fund Ltd., the entity described as the direct holder of the shares in Verastem, Inc. The filing states that "pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund." Armistice Capital is classified in the filing as an investment adviser and other organization (type "IA, OO").
Steven Boyd, identified as the managing member of Armistice Capital, LLC, is listed as a co-reporting person classified as a holding company and individual (type "HC, IN"). The filing notes that Boyd "may be deemed to beneficially own the securities of the Issuer held by the Master Fund" by virtue of his role. The Master Fund itself "specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital," according to the filing.
Verastem, Inc. is a biopharmaceutical company whose common stock is listed on NASDAQ:VSTM, with principal executive offices located at 117 Kendrick Street, Suite 500, Needham, MA 02494, as stated in the filing. The filing also includes a certification, signed by Boyd on November 16, 2026, that the reported securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."
What Was Disclosed
Armistice Capital, LLC and Steven Boyd disclosed beneficial ownership of 5,724,000 shares of Verastem, Inc. common stock, representing 0.94% of the class, with all voting and dispositive power held on a shared basis as of September 30, 2026.





Please wait processing your request...